Lv1
40 积分 2024-09-01 加入
Spatial determinants of antibody-drug conjugate SHR-A1811 efficacy in neoadjuvant treatment for HER2-positive breast cancer
5天前
已完结
AI-driven biomarkers for antibody-drug conjugates
5天前
已完结
Neoadjuvant chemotherapy combined with endocrine therapy for hormone receptor-positive breast cancer: A systematic review and meta-analysis
8天前
已完结
Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer
8天前
已完结
Pembrolizumab and chemotherapy in high-risk, early-stage, ER(+)/HER2(-) breast cancer: a randomized phase 3 trial
2个月前
已完结
Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer
2个月前
已完结
The hallmarks of cancer immune evasion
5个月前
已完结
Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer
5个月前
已完结
Spatial transcriptomics: a new frontier in accurate localization of breast cancer diagnosis and treatment
5个月前
已完结
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
5个月前
已完结
皖公网安备34019202002308
